ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 10 0 0 0 0 0
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 no 0 10 1 0 0 0 0
Advances in advances A Ad Adv Adva BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 0
Acta Dermato-Venereologica acta A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 - 1 10 0 0 0 0 0
ORIGINAL REPORT original O OR ORI ORIG BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 1 1 0 0 0
1/6 1/6 1/6 1 1/ 1/6 1/6 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 0 / 1 10 1 1 0 0 0
2024 ©Author(s). 2024 2 20 202 2024 BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS ALLDIGIT 0 0 0 0 1 0 0 0 0 0 ().,-. 6 10 0 1 0 0 0
the terms the t th the the BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 -.(://.//-/./). 15 8 0 1 0 0 0
SIGNIFICANCE SIGNIFICANCE significance S SI SIG SIGN BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 0 0 no 0 10 0 0 0 0 1
Upadacitinib is upadacitinib U Up Upa Upad BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 0 , 1 9 0 0 0 0 1
that causes that t th tha that BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 .- 2 9 0 0 0 0 1
ted the ted t te ted ted BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 0 0 "- 2 9 0 0 0 0 1
gets" with gets" g ge get gets BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 ", 2 9 0 0 0 0 1
multiple criteria multiple m mu mul mult BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,, 2 9 0 0 0 0 1
quality of quality q qu qua qual BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 9 0 0 0 0 1
mg, over mg, m mg mg, mg, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 , 1 9 0 0 0 0 1
of treatment, of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 ,- 2 9 0 0 0 0 1
the targets the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 .- 2 9 0 0 0 0 1
light the light l li lig ligh BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 0 - 1 10 0 0 0 0 1
pects of pects p pe pec pect BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 0 ' 1 9 0 0 0 0 1
for atopic for f fo for for BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 0 . 1 3 0 0 0 0 1
A treat-to-target a A A A A BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 0 2 -- 2 9 0 0 0 0 1
guide systemic guide g gu gui guid BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 - 1 9 0 0 0 0 1
matitis (AD). matitis m ma mat mati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 (). 3 9 0 0 0 0 1
a 3-month a a a a a BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 1 0 1 0 0 0 0 0 0 2 - 1 9 0 0 0 0 1
6-month optimal 6-month 6 6- 6-m 6-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 2 -,- 3 8 0 0 0 0 1
sessment of sessment s se ses sess BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 -, 2 9 0 0 0 0 1
as Eczema as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 , 1 9 0 0 0 0 1
an 11-point an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 2 -, 2 9 0 0 0 0 1
Quality Index, quality Q Qu Qua Qual BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 ,-. 3 8 0 0 0 0 1
Achievement of achievement A Ac Ach Achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 2 -- 2 8 0 0 0 0 1
citinib (15 citinib c ci cit citi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 ()- 3 8 0 0 0 0 1
ted using ted t te ted ted BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 0 2 no 0 9 0 0 0 0 1
and 2 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 9 0 0 0 0 1
with upadacitinib with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ,- 2 9 0 0 0 0 1
acceptable target acceptable a ac acc acce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ,, 2 8 0 0 0 0 1
≥87% of ≥87% ≥ ≥8 ≥87 ≥87% BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 0 2 ,- 2 9 0 0 0 0 1
achieved by achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 ,, 2 8 0 0 0 0 1
weeks 2, weeks w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 0 2 ,,,. 4 9 0 0 0 0 1
individual criteria individual i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 - 1 10 0 0 0 0 1
creased over creased c cr cre crea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 .- 2 9 0 0 0 0 1
citinib 15 citinib c ci cit citi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 no 0 8 0 0 0 0 1
of care of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 --- 3 9 0 0 0 0 1
hieving 6-month hieving h hi hie hiev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 0 2 - 1 9 0 0 0 0 1
as 2 as a as as as BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 2 . 1 5 0 0 0 0 1
Key words: key K Ke Key Key BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 1 1 0 0 0 0 0 0 5 :;;; 4 10 0 0 0 0 1
clearance; treat-to-target; clearance; c cl cle clea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 0 5 ;--;. 5 6 0 0 0 0 1
Submitted Aug submitted S Su Sub Subm BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 5 ,., 3 10 0 0 0 0 1
Published May published P Pu Pub Publ BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 5 ,.:./.. 7 10 0 0 0 0 1
Acta Derm acta A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 5 ;:. 3 10 0 0 0 0 1
Corr: Shawn corr: C Co Cor Corr BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 0 5 :.,, 4 9 0 0 0 0 1
University School university U Un Uni Univ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 0 5 ,,,, 4 10 0 0 0 0 1
21231, USA. 21231, 2 21 212 2123 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 0 5 ,.-:.@. 7 6 0 0 0 0 1
A topic a A A A A BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 1 6 (), 3 10 0 0 0 0 1
disease characterized disease d di dis dise BLOCKSTART PAGEIN SAMEFONT LOWERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 8 0 0 0 0 1
intense pruritus, intense i in int inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 , 1 8 0 0 0 0 1
substantial disease substantial s su sub subs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 - 1 9 0 0 0 0 1
quality of quality q qu qua qual BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ()(,). 6 9 0 0 0 0 1
treatments (such treatments t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ( 1 9 0 0 0 0 1
small-molecule oral small-molecule s sm sma smal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 -) 2 10 0 0 0 0 1
recommended for recommended r re rec reco BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 9 0 0 0 0 1
of AD of o of of of BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 8 0 0 0 0 1
with standard with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 (,).- 5 9 0 0 0 0 1
pies have pies p pi pie pies BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 8 0 0 0 0 1
improved the improved i im imp impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 - 1 9 0 0 0 0 1
to-severe AD; to-severe t to to- to-s BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 -;, 3 8 0 0 0 0 1
regarding optimal regarding r re reg rega BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 . 1 8 0 0 0 0 1
A treat-to-target a A A A A BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 1 0 1 0 0 0 0 0 1 6 -- 2 8 0 0 0 0 1
by de by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 -.()- 5 9 0 0 0 0 1
making concerning making m ma mak maki BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 9 0 0 0 0 1
in adults in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 6 .- 2 8 0 0 0 0 1
reported global reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 , 1 9 0 0 0 0 1
as well as a as as as BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 / 1 8 0 0 0 0 1
physicians of physicians p ph phy phys BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 8 0 0 0 0 1
signs, itch, signs, s si sig sign BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ,, 2 8 0 0 0 0 1
(5). Treatment (5). ( (5 (5) (5). BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 6 (). 3 9 0 0 0 0 1
to be to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 9 0 0 0 0 1
target to target t ta tar targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 no 0 9 0 0 0 0 1
initiation, each initiation, i in ini init BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ,- 2 8 0 0 0 0 1
reported global reported r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 ("") 4 9 0 0 0 0 1
plus at plus p pl plu plus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 6 (.)(). 6 10 0 0 0 0 1
treat-to-target framework treat-to-target t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 6 -- 2 9 0 0 0 0 1
AD treatment ad A AD AD AD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 1 6 ,,- 3 9 0 0 0 0 1
tion and tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 1 6 no 0 10 0 0 0 0 1
in setting in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 1 6 (). 3 7 0 0 0 0 1
Upadacitinib is upadacitinib U Up Upa Upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 6 no 0 9 0 0 0 0 1
(6, 7). (6, ( (6 (6, (6, BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 1 6 (,).- 5 9 0 0 0 0 1
Targeted Combined targeted T Ta Tar Targ BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 no 0 10 1 0 0 0 1
Domains in domains D Do Dom Doma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 :-- 3 9 1 0 0 0 1
Adults with adults A Ad Adu Adul BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 9 -- 2 10 1 0 0 0 1
Upadacitinib Upadacitinib upadacitinib U Up Upa Upad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 1 9 no 0 2 1 0 0 0 1
Shawn G. shawn S Sh Sha Shaw BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 1 10 .,-,.,,, 8 10 1 0 0 0 1
AYDIN 6 aydin A AY AYD AYDI BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 1 10 ,.,.,, 6 8 1 0 0 0 1
1 1 1 1 1 1 1 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 1 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 1 10 no 0 10 0 0 0 0 1
Department of department D De Dep Depa BLOCKSTART PAGEIN SAMEFONT HIGHERFONT 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 ,,,,,,, 7 10 0 0 0 0 1
the Netherlands, the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 1 10 ,,,,, 5 9 0 0 0 0 1
USA, 4 usa, U US USA USA, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 1 10 ,,,,,,, 7 9 0 0 0 0 1
Dermatology, Aarhus dermatology, D De Der Derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 ,,,,.,,,, 9 9 0 0 0 0 1
Allergy, University allergy, A Al All Alle BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 1 10 ,,,, 4 5 0 0 0 0 1
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 no 0 10 0 0 0 0 0
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 no 0 10 1 0 0 0 0
Advances in advances A Ad Adv Adva BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 10 0 0 0 0 0
Acta Dermato-Venereologica acta A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 - 1 10 1 0 0 0 0
S. G. s. S S. S. S. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 ..."--" 7 10 1 1 0 0 0
2/6 2/6 2/6 2 2/ 2/6 2/6 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 / 1 0 1 1 0 0 0
Acta Derm acta A Ac Act Acta BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 2 0 no 0 10 0 1 0 0 0
pared with pared p pa par pare BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 -- 2 9 1 0 0 0 1
AD in ad A AD AD AD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 2 0 ( 1 8 1 0 0 0 1
2) and 2) 2 2) 2) 2) BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 0 )--- 4 9 1 0 0 0 1
re AD re r re re re BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 (,).,-- 7 10 1 0 0 0 1
framework and framework f fr fra fram BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 8 1 0 0 0 1
and Measure and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 no 0 8 1 0 0 0 1
in AD in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 0 - 1 9 1 0 0 0 1
upadacitinib (15 upadacitinib u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 0 () 2 8 1 0 0 0 1
with moderate-to-severe with w wi wit with BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 0 --. 3 4 1 0 0 0 1
MATERIALS AND materials M MA MAT MATE BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 10 0 0 0 0 1
Study design, study S St Stu Stud BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 ,, 2 10 0 0 0 0 1
Measure Up measure M Me Mea Meas BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 ()() 4 8 0 0 0 0 1
are identical, are a ar are are BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 ,,-,, 5 9 0 0 0 0 1
3 studies 3 3 3 3 3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 2 1 no 0 9 0 0 0 0 1
treating patients treating t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 --(,). 6 9 0 0 0 0 1
criteria for criteria c cr cri crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 no 0 9 0 0 0 0 1
reported; in reported; r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 ;,(- 4 9 0 0 0 0 1
years, weight years, y ye yea year BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 ,)(-) 5 9 0 0 0 0 1
symptoms for symptoms s sy sym symp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 ,, 2 8 0 0 0 0 1
and had and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 --( 3 8 0 0 0 0 1
Area and area A Ar Are Area BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 [], 3 9 0 0 0 0 1
Global Assessment global G Gl Glo Glob BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 [-], 4 9 0 0 0 0 1
of Worst of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 [-], 4 8 0 0 0 0 1
and ≥ and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 )(). 4 10 0 0 0 0 1
randomized 1:1:1 randomized r ra ran rand BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 2 1 ::, 3 9 0 0 0 0 1
15 mg, 15 1 15 15 15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 2 1 ,,(). 5 9 0 0 0 0 1
At week at A At At At BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 ,-: 3 9 0 0 0 0 1
to upadacitinib to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 ; 1 9 0 0 0 0 1
blinded upadacitinib blinded b bl bli blin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 (,). 4 7 0 0 0 0 1
The study the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 ; 1 8 0 0 0 0 1
International Council international I In Int Inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 1 ;- 2 8 0 0 0 0 1
cable regulations, cable c ca cab cabl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 2 1 ,, 2 9 0 0 0 0 1
from the from f fr fro from BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 . 1 9 0 0 0 0 1
informed consent. informed i in inf info BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 1 . 1 2 0 0 0 0 1
Assessments and assessments A As Ass Asse BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 3 no 0 10 0 0 0 0 1
Patient-reported global patient-reported P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 3 - 1 9 0 0 0 0 1
the Patient the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 -(-; 4 9 0 0 0 0 1
0=clear, 1=almost 0=clear, 0 0= 0=c 0=cl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 2 3 ,,,,).- 7 9 0 0 0 0 1
is derived is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 -()(). 6 10 0 0 0 0 1
domains were domains d do dom doma BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 no 0 8 0 0 0 0 1
and HRQoL: and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 2 3 :,(), 5 8 0 0 0 0 1
WP-NRS, Dermatology wp-nrs, W WP WP- WP-N BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 2 3 -,(),- 6 8 0 0 0 0 1
Oriented Eczema oriented O Or Ori Orie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 3 (). 3 4 0 0 0 0 1
This analysis this T Th Thi This BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 3 no 0 8 0 0 0 0 1
Measure Up measure M Me Mea Meas BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 2 3 no 0 8 0 0 0 0 1
at baseline: at a at at at BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 :,-(..,), 9 10 1 0 0 0 1
EASI>7, SCORAD>24, easi>7, E EA EAS EASI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 ,,-,,. 6 7 1 0 0 0 1
Integrated patient integrated I In Int Inte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 8 1 0 0 0 1
Up 2 up U Up Up Up BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
who achieved who w wh who who BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 - 1 9 1 0 0 0 1
6-month optimal 6-month 6 6- 6-m 6-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 4 -,,( 4 9 1 0 0 0 1
at which at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 4 no 0 9 1 0 0 0 1
1 and 1 1 1 1 1 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 3 4 ). 2 2 1 0 0 0 1
Statistical analysis statistical S St Sta Stat BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 10 0 0 0 0 1
Data are data D Da Dat Data BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 5 -- 2 9 0 0 0 0 1
surements at surements s su sur sure BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 ;- 2 9 0 0 0 0 1
tistical comparisons tistical t ti tis tist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 no 0 9 0 0 0 0 1
performed for performed p pe per perf BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 . 1 9 0 0 0 0 1
time points time t ti tim time BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 9 0 0 0 0 1
were conducted were w we wer were BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 8 0 0 0 0 1
(weeks 2, (weeks ( (w (we (wee BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 (,,). 5 10 0 0 0 0 1
vs placebo vs v vs vs vs BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 (),- 4 9 0 0 0 0 1
responder imputation responder r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 5 no 0 9 0 0 0 0 1
owing to owing o ow owi owin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 -(-).- 6 8 0 0 0 0 1
intervals for intervals i in int inte BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 5 no 0 10 0 0 0 0 1
Fig. 1. fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 ..- 3 10 1 0 0 0 1
and the and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 -.: 3 8 1 0 0 0 1
Life Quality life L Li Lif Life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 ;:; 3 9 1 0 0 0 1
PGIS-5: Patient pgis-5: P PG PGI PGIS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 6 -:-; 4 9 1 0 0 0 1
POEM: Patient-Oriented poem: P PO POE POEM BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 :-;: 4 8 1 0 0 0 1
of Atopic of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 ;-: 3 9 1 0 0 0 1
Scale. a scale. S Sc Sca Scal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 6 .--(, 5 9 1 0 0 0 1
clear, 2=mild, clear, c cl cle clea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 3 6 ,,,). 5 5 1 0 0 0 1
Table I. table T Ta Tab Tabl BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 . 1 10 0 0 0 0 1
Characteristic Characteristic characteristic C Ch Cha Char BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 10 0 0 0 0 1
UPA 30 upa U UP UPA UPA BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 7 no 0 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 () 2 10 0 0 0 0 1
UPA 15 upa U UP UPA UPA BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 7 no 0 10 0 0 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 () 2 10 0 0 0 0 1
PBO PBO pbo P PB PBO PBO BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 3 7 no 0 4 0 0 0 0 1
(n = (n ( (n (n (n BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 3 7 () 2 10 0 0 0 0 1
Age, years, age, A Ag Age Age, BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 ,,() 4 10 0 0 0 0 1
36.3 (14.9) 36.3 3 36 36. 36.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 .(.) 4 5 0 0 0 0 1
35.9 (14.6) 35.9 3 35 35. 35.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 .(.) 4 5 0 0 0 0 1
36.8 (14.0) 36.8 3 36 36. 36.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 3 7 .(.) 4 5 0 0 0 0 1
Sex, n sex, S Se Sex Sex, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 ,() 3 5 0 0 0 0 1
Female Female female F Fe Fem Fema BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 3 0 0 0 0 1
191 (45.0) 191 1 19 191 191 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
183 (42.8) 183 1 18 183 183 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
196 (45.6) 196 1 19 196 196 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
Male Male male M Ma Mal Male BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 2 0 0 0 0 1
233 (55.0) 233 2 23 233 233 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
245 (57.2) 245 2 24 245 245 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
234 (54.4) 234 2 23 234 234 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
Race, n race, R Ra Rac Race BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 ,() 3 5 0 0 0 0 1
White White white W Wh Whi Whit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 3 7 no 0 2 0 0 0 0 1
290 (68.4) 290 2 29 290 290 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
278 (65.0) 278 2 27 278 278 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
281 (65.3) 281 2 28 281 281 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
Black Black black B Bl Bla Blac BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 3 7 no 0 2 0 0 0 0 1
17 (4.0) 17 1 17 17 17 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 4 0 0 0 0 1
29 (6.8) 29 2 29 29 29 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 4 0 0 0 0 1
30 (7.0) 30 3 30 30 30 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 4 0 0 0 0 1
Asian Asian asian A As Asi Asia BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 2 0 0 0 0 1
102 (24.1) 102 1 10 102 102 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
109 (25.5) 109 1 10 109 109 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
104 (24.2) 104 1 10 104 104 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 5 0 0 0 0 1
Other Other other O Ot Oth Othe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 3 7 no 0 2 0 0 0 0 1
15 (3.5) 15 1 15 15 15 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 4 0 0 0 0 1
12 (2.8) 12 1 12 12 12 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 4 0 0 0 0 1
15 (3.5) 15 1 15 15 15 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 3 7 (.) 3 4 0 0 0 0 1
Body mass body B Bo Bod Body BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 ,/,().(.) 9 10 0 0 0 0 1
26.1 (5.7) 26.1 2 26 26. 26.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
26.9 (6.0) 26.9 2 26 26. 26.9 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
BSA affected, bsa B BS BSA BSA BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 ,,() 4 5 0 0 0 0 1
47.4 (22.5) 47.4 4 47 47. 47.4 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
47.3 (22.4) 47.3 4 47 47. 47.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
47.0 (22.5) 47.0 4 47 47. 47.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
Previous systemic previous P Pr Pre Prev BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 ,()(.) 6 9 0 0 0 0 1
232 (54.2) 232 2 23 232 232 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
238 (55.3) 238 2 23 238 238 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
Disease duration, disease D Di Dis Dise BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 ,,().(.) 8 10 0 0 0 0 1
24.3 (14.7) 24.3 2 24 24. 24.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
25.6 (14.1) 25.6 2 25 25. 25.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
vIGA-AD score, viga-ad v vI vIG vIGA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 8 -,() 4 4 0 0 0 0 1
Moderate (score moderate M Mo Mod Mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 () 2 4 0 0 0 0 1
200 (47.2) 200 2 20 200 200 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
209 (48.8) 209 2 20 209 209 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
206 (47.9) 206 2 20 206 206 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
Severe (score severe S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 () 2 4 0 0 0 0 1
224 (52.8) 224 2 22 224 224 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
219 (51.2) 219 2 21 219 219 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
224 (52.1) 224 2 22 224 224 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
PGIS-5, n pgis-5, P PG PGI PGIS BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 -,() 4 2 0 0 0 0 1
Moderate (score moderate M Mo Mod Mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 () 2 4 0 0 0 0 1
193 (45.5) 193 1 19 193 193 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
201 (47.0) 201 2 20 201 201 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
181 (42.1) 181 1 18 181 181 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
Severe (score severe S Se Sev Seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 () 2 4 0 0 0 0 1
231 (54.5) 231 2 23 231 231 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
227 (53.0) 227 2 22 227 227 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
249 (57.9) 249 2 24 249 249 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 4 8 (.) 3 2 0 0 0 0 1
EASI, mean easi, E EA EAS EASI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 ,() 3 3 0 0 0 0 1
29.8 (11.7) 29.8 2 29 29. 29.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
29.9 (12.3) 29.9 2 29 29. 29.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
29.0 (12.1) 29.0 2 29 29. 29.0 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
SCORAD, mean scorad, S SC SCO SCOR BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 ,() 3 3 0 0 0 0 1
68.1 (12.3) 68.1 6 68 68. 68.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
68.1 (12.5) 68.1 6 68 68. 68.1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
67.8 (12.1) 67.8 6 67 67. 67.8 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
WP-NRS, mean wp-nrs, W WP WP- WP-N BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 -,() 4 3 0 0 0 0 1
7.5 (1.4) 7.5 7 7. 7.5 7.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
7.3 (1.5) 7.3 7 7. 7.3 7.3 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
7.5 (1.5) 7.5 7 7. 7.5 7.5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
DLQI, mean dlqi, D DL DLQ DLQI BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 8 ,() 3 3 0 0 0 0 1
17.6 (6.3) 17.6 1 17 17. 17.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
17.6 (6.6) 17.6 1 17 17. 17.6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
18.2 (6.3) 18.2 1 18 18. 18.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
POEM, mean poem, P PO POE POEM BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 4 8 ,() 3 3 0 0 0 0 1
22.2 (4.8) 22.2 2 22 22. 22.2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
21.9 (4.4) 21.9 2 21 21. 21.9 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
22.6 (4.5) 22.6 2 22 22. 22.6 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 8 .(.) 4 2 0 0 0 0 1
BSA: body bsa: B BS BSA BSA: BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 11 :;:;: 5 9 0 0 0 0 1
Area and area A Ar Are Area BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 ;-:- 4 9 0 0 0 0 1
scale; PBO: scale; s sc sca scal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 11 ;:;:-;: 7 9 0 0 0 0 1
of Atopic of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 11 ;:;-: 5 9 0 0 0 0 1
Assessment for assessment A As Ass Asse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 11 ;-:. 4 10 0 0 0 0 1
PGIS-5 is pgis-5 P PG PGI PGIS BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 11 --()(). 7 7 0 0 0 0 1
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 10 1 0 0 0 0
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 10 1 0 0 0 0
Advances in advances A Ad Adv Adva BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 4 0 no 0 10 0 0 0 0 0
Acta Dermato-Venereologica acta A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 - 1 10 1 0 0 0 0
3/6 3/6 3/6 3 3/ 3/6 3/6 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 4 0 / 1 0 1 1 0 0 0
S. G. s. S S. S. S. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 ..."--" 7 10 1 1 0 0 0
Acta Derm acta A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 4 0 no 0 10 1 1 0 0 0
the Cochran-Mantel-Haenszel the t th the the BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 4 0 --( 3 10 1 0 0 0 1
baseline vIGA-AD). baseline b ba bas base BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 4 0 -). 3 2 1 0 0 0 1
RESULTS RESULTS results R RE RES RESU BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 ALLCAP NODIGIT 0 1 1 0 0 0 0 0 5 1 no 0 10 1 0 0 0 1
Patients Patients patients P Pa Pat Pati BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 no 0 10 1 0 0 0 1
Overall, this overall, O Ov Ove Over BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 1 ,,( 3 10 1 0 0 0 1
30 mg, 30 3 30 30 30 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 5 1 ,;,;, 5 9 1 0 0 0 1
n = n n n n n BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 1 ).- 3 8 1 0 0 0 1
ristics were ristics r ri ris rist BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 1 no 0 9 1 0 0 0 1
groups (Table groups g gr gro grou BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 ().'().(.) 10 9 1 0 0 0 1
years; 44.5% years; y ye yea year BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 ;.; 3 9 1 0 0 0 1
(66.2%) were (66.2%) ( (6 (66 (66. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 1 (.).,() 7 8 1 0 0 0 1
score was score s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 .(.);.- 7 9 1 0 0 0 1
score of score s sc sco scor BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 ();()- 6 8 1 0 0 0 1
was 7.4 was w wa was was BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 1 .(.). 5 2 1 0 0 0 1
Achievement of achievement A Ac Ach Achi BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 3 - 1 10 1 0 0 0 1
More than more M Mo Mor More BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 9 1 0 0 0 1
upadacitinib achieved upadacitinib u up upa upad BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 -- 2 10 1 0 0 0 1
get goal get g ge get get BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 , 1 10 1 0 0 0 1
at week at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 ;- 2 9 1 0 0 0 1
tion of tion t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 - 1 9 1 0 0 0 1
target goal target t ta tar targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 (.). 4 10 1 0 0 0 1
More than more M Mo Mor More BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 8 1 0 0 0 1
achieved all achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 - 1 9 1 0 0 0 1
initial acceptable initial i in ini init BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 , 1 9 1 0 0 0 1
over 51% over o ov ove over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 9 1 0 0 0 1
at weeks at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 (.). 4 8 1 0 0 0 1
consistent using consistent c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 -; 2 8 1 0 0 0 1
achieved the achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 - 1 9 1 0 0 0 1
upadacitinib 15 upadacitinib u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 5 4 no 0 9 1 0 0 0 1
2 and 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 5 4 (.;.). 6 9 1 0 0 0 1
the full the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 - 1 10 1 0 0 0 1
initial acceptable initial i in ini init BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 , 1 10 1 0 0 0 1
achieving a achieving a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 no 0 9 1 0 0 0 1
increased over increased i in inc incr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 ; 1 9 1 0 0 0 1
higher with higher h hi hig high BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 (.). 4 8 1 0 0 0 1
Among subgroups among A Am Amo Amon BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 4 - 1 8 1 0 0 0 1
patient domain patient p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 (--) 4 9 1 0 0 0 1
and ≥ and a an and and BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 4 ,,,- 4 10 1 0 0 0 1
Fig. 2. fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 9 .. 2 6 1 0 0 0 1
p a p p p p p BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 5 9 no 0 10 1 0 0 0 1
3-month targets 3-month 3 3- 3-m 3-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 - 1 6 1 0 0 0 1
time (OC). time t ti tim time BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 ().: 4 7 1 0 0 0 1
cases. (A) cases. c ca cas case BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 .() 3 7 1 0 0 0 1
for patients for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 no 0 7 1 0 0 0 1
3-month initial 3-month 3 3- 3-m 3-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 - 1 7 1 0 0 0 1
target goal target t ta tar targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 () 2 8 1 0 0 0 1
achieving all achieving a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 9 no 0 7 1 0 0 0 1
3-month targets. 3-month 3 3- 3-m 3-mo BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 5 9 -. 2 5 1 0 0 0 1
Fig. 3. fig. F Fi Fig Fig. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 .. 2 8 1 0 1 1 1
individual components individual i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 11 - 1 8 1 0 0 0 1
acceptable target acceptable a ac acc acce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 5 11 ().:; 5 9 1 0 0 0 1
PBO: placebo; pbo: P PB PBO PBO: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 5 11 :;-: 4 10 1 0 0 0 1
Severity 5-point severity S Se Sev Seve BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 5 11 -;:. 4 8 1 0 0 0 1
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 10 1 0 0 0 0
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 10 1 0 0 0 0
Advances in advances A Ad Adv Adva BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 0 no 0 10 0 0 0 0 0
Acta Dermato-Venereologica acta A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 - 1 10 1 0 0 0 0
S. G. s. S S. S. S. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 ..."--" 7 10 1 1 0 0 0
4/6 4/6 4/6 4 4/ 4/6 4/6 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 0 / 1 0 1 1 0 0 0
Acta Derm acta A Ac Act Acta BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 6 0 no 0 10 1 1 0 0 0
components, the components, c co com comp BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 , 1 9 1 0 0 0 1
specific individual specific s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 0 -- 2 10 1 0 0 0 1
sented in sented s se sen sent BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 0 .-. 3 4 1 0 0 0 1
Achievement of achievement A Ac Ach Achi BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 1 - 1 10 1 0 0 0 1
Overall, results overall, O Ov Ove Over BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 1 ,-- 3 9 1 0 0 0 1
lowed similar lowed l lo low lowe BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 - 1 9 1 0 0 0 1
initial acceptable initial i in ini init BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 ., 2 9 1 0 0 0 1
patients who patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 - 1 9 1 0 0 0 1
optimal target optimal o op opt opti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 (.) 3 9 1 0 0 0 1
6 of 6 6 6 6 6 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 1 -(.). 5 9 1 0 0 0 1
2 and 2 2 2 2 2 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 1 ,-, 3 8 1 0 0 0 1
6-month optimal 6-month 6 6- 6-m 6-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 1 - 1 9 1 0 0 0 1
30 mg 30 3 30 30 30 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 6 1 (.;.). 6 9 1 0 0 0 1
Similar to similar S Si Sim Simi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 1 -- 2 10 1 0 0 0 1
dings, the dings, d di din ding BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 1 ,- 2 9 1 0 0 0 1
achieved by achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 no 0 9 1 0 0 0 1
across the across a ac acr acro BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 , 1 9 1 0 0 0 1
rates were rates r ra rat rate BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 1 no 0 9 1 0 0 0 1
with placebo with w wi wit with BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 (.). 4 8 1 0 0 0 1
who achieved who w wh who who BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 -(- 3 9 1 0 0 0 1
5 score 5 5 5 5 5 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 1 0 0 0 0 0 0 0 6 5 ),,, 4 10 1 0 0 0 1
6-month target 6-month 6 6- 6-m 6-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 5 -, 2 9 1 0 0 0 1
who achieved who w wh who who BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 5 -- 2 9 1 0 0 0 1
ponents is ponents p po pon pone BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 5 .-. 3 6 1 0 0 0 1
DISCUSSION DISCUSSION discussion D DI DIS DISC BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 10 0 0 0 0 1
The treat-to-target the T Th The The BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 7 --,- 4 8 1 0 0 0 1
ments in ments m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 ' 1 9 1 0 0 0 1
severity and severity s se sev seve BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 9 1 0 0 0 1
by the by b by by by BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 /- 2 10 1 0 0 0 1
ments, provides ments, m me men ment BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 7 , 1 9 1 0 0 0 1
for systemic for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 9 1 0 0 0 1
treatment success treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 .,- 3 9 1 0 0 0 1
acceptable target acceptable a ac acc acce BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 - 1 9 1 0 0 0 1
goal were goal g go goa goal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 no 0 9 1 0 0 0 1
at the at a at at at BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 7 .- 2 9 1 0 0 0 1
Fig. 4. fig. F Fi Fig Fig. BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 9 .. 2 6 1 0 0 0 1
p a p p p p p BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 1 0 0 0 0 0 0 0 6 9 no 0 10 1 0 0 0 1
6-month targets 6-month 6 6- 6-m 6-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 - 1 6 1 0 0 0 1
time (OC). time t ti tim time BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 ().: 4 7 1 0 0 0 1
cases. (A) cases. c ca cas case BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 .() 3 7 1 0 0 0 1
for patients for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 no 0 7 1 0 0 0 1
6-month optimal 6-month 6 6- 6-m 6-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 6 9 - 1 8 1 0 0 0 1
and (B) and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 () 2 7 1 0 0 0 1
all 6 all a al all all BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 - 1 7 1 0 0 0 1
targets. targets. targets. t ta tar targ BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 9 . 1 2 1 0 0 0 1
Fig. 5. fig. F Fi Fig Fig. BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 .. 2 9 1 0 1 0 1
individual components individual i in ind indi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 - 1 8 1 0 0 0 1
optimal target optimal o op opt opti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 ().: 4 8 1 0 0 0 1
cases; PBO: cases; c ca cas case BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 6 10 ;:;-: 5 10 1 0 0 0 1
Impression of impression I Im Imp Impr BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 6 10 -;: 3 9 1 0 0 0 1
upadacitinib. upadacitinib. upadacitinib. u up upa upad BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 1 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 6 10 . 1 3 1 0 0 0 1
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 10 0 0 0 0 0
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 10 0 0 0 0 0
Advances in advances A Ad Adv Adva BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 10 0 0 0 0 0
Acta Dermato-Venereologica acta A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 - 1 10 0 0 0 0 0
5/6 5/6 5/6 5 5/ 5/6 5/6 BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 / 1 0 0 1 0 0 0
S. G. s. S S. S. S. BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 ..."--" 7 10 0 1 0 0 0
Acta Derm acta A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 10 0 1 0 0 0
tion of tion t ti tio tion BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 -- 2 9 0 0 0 0 1
goals with goals g go goa goal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
mg, a mg, m mg mg, mg, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ,- 2 8 0 0 0 0 1
upadacitinib studies upadacitinib u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 (,). 4 4 0 0 0 0 1
Patients rapidly patients P Pa Pat Pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
upadacitinib 15 upadacitinib u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 :- 2 9 0 0 0 0 1
initial acceptable initial i in ini init BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
6-month optimal 6-month 6 6- 6-m 6-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 -, 2 9 0 0 0 0 1
or improved or o or or or BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .- 2 8 0 0 0 0 1
ring how ring r ri rin ring BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
and 6-month and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -, 2 8 0 0 0 0 1
findings suggest findings f fi fin find BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
be re-evaluated be b be be be BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
rapid efficacy rapid r ra rap rapi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
become elevated. become b be bec beco BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ., 2 8 0 0 0 0 1
the treat-to-target the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -- 2 9 0 0 0 0 1
to adapt to t to to to BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
AD or ad A AD AD AD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
systems (12, systems s sy sys syst BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 (,). 4 2 0 0 0 0 1
Overall, the overall, O Ov Ove Over BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 ,- 2 8 0 0 0 0 1
and the and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
more than more m mo mor more BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
three-quarters of three-quarters t th thr thre BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -. 2 8 0 0 0 0 1
of patients of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
also increased also a al als also BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .,- 3 8 0 0 0 0 1
of patients of o of of of BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
9-16% of 9-16% 9 9- 9-1 9-16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 7 0 -- 2 8 0 0 0 0 1
targets. At targets. t ta tar targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 .,- 3 9 0 0 0 0 1
achieved all achieved a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
half achieved half h ha hal half BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -. 2 8 0 0 0 0 1
findings highlight findings f fi fin find BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 9 0 0 0 0 1
sociated with sociated s so soc soci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 . 1 5 0 0 0 0 1
Numerous systemic numerous N Nu Num Nume BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
loped and loped l lo lop lope BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ;,- 3 9 0 0 0 0 1
sus exists sus s su sus sus BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 10 0 0 0 0 1
success. Furthermore, success. s su suc succ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ., 2 9 0 0 0 0 1
may be may m ma may may BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 1 0 0 7 0 , 1 8 0 0 0 0 1
benefits may benefits b be ben bene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 .-- 3 9 0 0 0 0 1
was designed was w wa was was BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 - 1 8 0 0 0 0 1
mic therapies mic m mi mic mic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
patient populations. patient p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 9 0 0 0 0 1
criteria provides criteria c cr cri crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
response across response r re res resp BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
decision-making between decision-making d de dec deci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 -- 2 8 0 0 0 0 1
viders as viders v vi vid vide BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
optimal outcomes. optimal o op opt opti BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 . 1 9 0 0 0 0 1
the importance the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
dimensions of dimensions d di dim dime BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 (- 2 8 0 0 0 0 1
in addition in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 7 0 -) 2 9 0 0 0 0 1
treatment selection, treatment t tr tre trea BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 , 1 8 0 0 0 0 1
plans, and plans, p pl pla plan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 ,. 2 8 0 0 0 0 1
The results the T Th The The BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 8 0 0 0 0 1
with those with w wi wit with BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 --- 3 9 0 0 0 0 1
lective Janus lective l le lec lect BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 7 0 ,(), 4 9 0 0 0 0 1
demonstrates the demonstrates d de dem demo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
efficacy of efficacy e ef eff effi BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 7 0 no 0 9 0 0 0 0 1
outcomes. Generally, outcomes. o ou out outc BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ., 2 9 0 0 0 0 1
patients achieved patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 -- 2 8 0 0 0 0 1
target components target t ta tar targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
16 than 16 1 16 16 16 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS ALLDIGIT 0 0 0 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
week 12 week w we wee week BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 ( 1 8 0 0 0 0 1
have not have h ha hav have BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 )().- 5 9 0 0 0 0 1
port the port p po por port BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 -(-)-(-) 8 8 0 0 0 0 1
achievement of achievement a ac ach achi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 -- 2 8 0 0 0 0 1
upadacitinib therapy, upadacitinib u up upa upad BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 6 , 1 9 0 0 0 0 1
patients achieving patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 no 0 9 0 0 0 0 1
3-month and 3-month 3 3- 3-m 3-mo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 8 6 --;, 4 8 0 0 0 0 1
this is this t th thi this BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 6 . 1 10 0 0 0 0 1
Limitations Limitations limitations L Li Lim Limi BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 10 0 0 0 0 1
There are there T Th The Ther BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 8 7 . 1 9 0 0 0 0 1
is a is i is is is BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 9 0 0 0 0 1
and 2 and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 ;- 2 9 0 0 0 0 1
refore, whether refore, r re ref refo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 , 1 9 0 0 0 0 1
the nature the t th the the BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 9 0 0 0 0 1
not known. not n no not not BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 ., 2 9 0 0 0 0 1
population may population p po pop popu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 - 1 9 0 0 0 0 1
population of population p po pop popu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 . 1 9 0 0 0 0 1
assessments needed assessments a as ass asse BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 -- 2 9 0 0 0 0 1
target criteria target t ta tar targ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 9 0 0 0 0 1
fully integrated fully f fu ful full BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 9 0 0 0 0 1
such as such s su suc such BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 9 0 0 0 0 1
specific tools; specific s sp spe spec BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 ;, 2 9 0 0 0 0 1
implement these implement i im imp impl BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 9 0 0 0 0 1
can determine can c ca can can BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 .- 2 8 0 0 0 0 1
tion, these tion, t ti tio tion BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 , 1 9 0 0 0 0 1
benefits experienced benefits b be ben bene BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 7 ;-- 3 9 0 0 0 0 1
goals only goals g go goa goal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 """", 5 9 0 0 0 0 1
partial improvements partial p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 /- 2 8 0 0 0 0 1
mes that mes m me mes mes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 -- 2 10 0 0 0 0 1
be meaningful be b be be be BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 , 1 9 0 0 0 0 1
their disease their t th the thei BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 .-- 3 9 0 0 0 0 1
criteria do criteria c cr cri crit BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 - 1 9 0 0 0 0 1
ding their ding d di din ding BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 8 7 ;, 2 9 0 0 0 0 1
tailoring and tailoring t ta tai tail BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 - 1 9 0 0 0 0 1
and physicians and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 no 0 8 0 0 0 0 1
treatment goals. treatment t tr tre trea BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 7 . 1 2 0 0 0 0 1
Conlusion Conlusion conlusion C Co Con Conl BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 1 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 10 no 0 10 0 0 0 0 1
Upadacitinib 15-mg upadacitinib U Up Upa Upad BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 8 10 -- 2 9 0 0 0 0 1
durable improvements durable d du dur dura BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 10 no 0 8 0 0 0 0 1
life based life l li lif life BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 10 -,--, 5 10 0 0 0 0 1
which may which w wh whi whic BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 10 - 1 8 0 0 0 0 1
patients and patients p pa pat pati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 8 10 no 0 8 0 0 0 0 1
standards of standards s st sta stan BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 8 10 . 1 4 0 0 0 0 1
ACKNOWLEDGEMENTS ACKNOWLEDGEMENTS acknowledgements A AC ACK ACKN BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 9 11 no 0 10 0 0 0 0 1
AbbVie funded abbvie A Ab Abb AbbV BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 11 ,- 2 9 0 0 0 0 1
search, analysis, search, s se sea sear BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 11 ,,,,, 5 10 0 0 0 0 1
and approval and a an and and BLOCKEND PAGEEND SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 11 . 1 9 0 0 0 0 1
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGESTART NEWFONT HIGHERFONT 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 0 0 0 0
ActaDV ActaDV actadv A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 0 0 0 0
Advances in advances A Ad Adv Adva BLOCKSTART PAGEIN NEWFONT LOWERFONT 1 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 10 0 0 0 0 0
Acta Dermato-Venereologica acta A Ac Act Acta BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 1 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 - 1 10 0 0 0 0 0
S. G. s. S S. S. S. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 1 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ..."--" 7 10 0 1 0 0 0
6/6 6/6 6/6 6 6/ 6/6 6/6 BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 1 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 9 0 / 1 0 0 1 0 0 0
Acta Derm acta A Ac Act Acta BLOCKSTART PAGEIN NEWFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 1 0 0 0
data and data d da dat data BLOCKSTART PAGEIN NEWFONT HIGHERFONT 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,, 2 9 0 0 0 0 1
publication. No publication. p pu pub publ BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .. 2 9 0 0 0 0 1
AbbVie and abbvie A Ab Abb AbbV BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 no 0 10 0 0 0 0 1
who participated who w wh who who BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
provided by provided p pr pro prov BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ..,,,, 6 9 0 0 0 0 1
and funded and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 3 0 0 0 0 1
Data sharing data D Da Dat Data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 : 1 9 0 0 0 0 1
sharing regarding sharing s sh sha shar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 .- 2 9 0 0 0 0 1
cess to cess c ce ces cess BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,-( 4 9 0 0 0 0 1
sets), as sets), s se set sets BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ),(.., 6 9 0 0 0 0 1
reports, or reports, r re rep repo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,), 3 10 0 0 0 0 1
ongoing or ongoing o on ong ongo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
for clinical for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
These clinical these T Th The Thes BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 - 1 9 0 0 0 0 1
searchers who searchers s se sea sear BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ,, 2 9 0 0 0 0 1
and will and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 9 0 0 0 0 1
proposal, Statistical proposal, p pr pro prop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,(), 4 8 0 0 0 0 1
Data Sharing data D Da Dat Data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 (). 3 8 0 0 0 0 1
at any at a at at at BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 9 0 0 0 0 1
after acceptance after a af aft afte BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
be accessible be b be be be BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,- 2 8 0 0 0 0 1
red. For red. r re red red. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ., 2 9 0 0 0 0 1
visit the visit v vi vis visi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 :://./// 8 8 0 0 0 0 1
then select then t th the then BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 "". 3 2 0 0 0 0 1
Disclosures: SGK disclosures: D Di Dis Disc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 :/- 3 9 0 0 0 0 1
tant for tant t ta tan tant BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,,, 6 9 0 0 0 0 1
Celldex, Galderma, celldex, C Ce Cel Cell BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,, 5 8 0 0 0 0 1
Pharma, Novartis, pharma, P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,. 5 9 0 0 0 0 1
an investigator an a an an an BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 9 0 ,,,.- 5 9 0 0 0 0 1
has served has h ha has has BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,,/ 3 9 0 0 0 0 1
for AbbVie, for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,,,,,, 6 8 0 0 0 0 1
Pfizer, Regeneron, pfizer, P Pf Pfi Pfiz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,-,. 5 8 0 0 0 0 1
honoraria as honoraria h ho hon hono BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,/ 3 9 0 0 0 0 1
for AbbVie, for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,,,,,,, 7 8 0 0 0 0 1
Asana, ASLAN, asana, A As Asa Asan BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,,,,, 8 8 0 0 0 0 1
Celgene, Connect, celgene, C Ce Cel Celg BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,,, 6 8 0 0 0 0 1
GSK, Incyte, gsk, G GS GSK GSK, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,,,, 7 8 0 0 0 0 1
Optum, Pfizer, optum, O Op Opt Optu BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,-,, 7 8 0 0 0 0 1
and Union. and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 8 0 0 0 0 1
and Pfizer. and a an and and BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ./, 3 9 0 0 0 0 1
AOBiome, the aobiome, A AO AOB AOBi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,/- 4 8 0 0 0 0 1
nofi Genzyme. nofi n no nof nofi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 .', 3 9 0 0 0 0 1
Incyte, L'Oréal, incyte, I In Inc Incy BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,',,,,/ 7 9 0 0 0 0 1
Genzyme. He genzyme. G Ge Gen Genz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 . 1 8 0 0 0 0 1
participating on participating p pa par part BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,,, 3 9 0 0 0 0 1
AOBiome, Arbonne, aobiome, A AO AOB AOBi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,, 5 8 0 0 0 0 1
Burt's Bees, burt's B Bu Bur Burt BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ',(),, 6 8 0 0 0 0 1
Exeltis, Galderma, exeltis, E Ex Exe Exel BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,- 5 8 0 0 0 0 1
Clark, Kiniksa, clark, C Cl Cla Clar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,',,,, 7 9 0 0 0 0 1
Merck, Micreos merck, M Me Mer Merc BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,(),-,-, 8 9 0 0 0 0 1
Pfizer, Realm pfizer, P Pf Pfi Pfiz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,/, 4 8 0 0 0 0 1
Health, Theraplex, health, H He Hea Heal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 9 0 ,,,,., 6 9 0 0 0 0 1
has a has h ha has has BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 no 0 9 0 0 0 0 1
payments for payments p pa pay paym BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 9 0 0 0 0 1
advisory committee advisory a ad adv advi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 . 1 8 0 0 0 0 1
MD has md M MD MD MD BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 /, 2 9 0 0 0 0 1
consulting, and/or consulting, c co con cons BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 9 0 ,/, 3 9 0 0 0 0 1
Almirall, Arena, almirall, A Al Alm Almi BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,,, 6 8 0 0 0 0 1
Pharma, Lilly, pharma, P Ph Pha Phar BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 ,,,,,- 6 9 0 0 0 0 1
zyme. HA, zyme. z zy zym zyme BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 9 0 .,,,,- 6 8 0 0 0 0 1
AbbVie Inc., abbvie A Ab Abb AbbV BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 9 0 .,,,/ 5 8 0 0 0 0 1
patents. SW patents. p pa pat pate BLOCKSTART PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 ., 2 10 0 0 0 0 1
Pfizer, and pfizer, P Pf Pfi Pfiz BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,;- 3 9 0 0 0 0 1
tures for tures t tu tur ture BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 ,,,,, 5 9 0 0 0 0 1
Pharma, Lilly, pharma, P Ph Pha Phar BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,,,,. 5 8 0 0 0 0 1
REFERENCES REFERENCES references R RE REF REFE BLOCKSTART PAGEIN NEWFONT HIGHERFONT 1 0 ALLCAP NODIGIT 0 0 1 0 0 0 0 0 10 6 no 0 10 0 0 0 0 1
1. Langan 1. 1 1. 1. 1. BLOCKSTART PAGEIN NEWFONT LOWERFONT 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,.. 5 9 0 0 0 0 1
2020; 396: 2020; 2 20 202 2020 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 6 ;:-. 4 3 0 0 0 0 1
2. Elsawi 2. 2 2. 2. 2. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,,, 6 8 0 0 0 0 1
Capozza K, capozza C Ca Cap Capo BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,. 2 8 0 0 0 0 1
dermatitis among dermatitis d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 :. 2 9 0 0 0 0 1
JAMA Dermatol jama J JA JAM JAMA BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 1 0 0 0 0 0 0 10 6 ;:-. 4 5 0 0 0 0 1
3. Bieber 3. 3 3. 3. 3. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 ..: 3 10 0 0 0 0 1
for a for f fo for for BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 .;:-. 5 9 0 0 0 0 1
4. Paller 4. 4 4. 4. 4. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,. 4 9 0 0 0 0 1
atopic dermatitis: atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 :? 2 9 0 0 0 0 1
2017; 140: 2017; 2 20 201 2017 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 6 ;:-. 4 3 0 0 0 0 1
5. de 5. 5 5. 5. 5. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .-,,, 5 9 0 0 0 0 1
M, Foley m, M M, M, M, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,,,.-- 6 8 0 0 0 0 1
dermatitis: an dermatitis: d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 : 1 8 0 0 0 0 1
decision points decision d de dec deci BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 . 1 8 0 0 0 0 1
2021; 101: 2021; 2 20 202 2021 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 6 ;:. 3 3 0 0 0 0 1
6. Parmentier 6. 6 6. 6. 6. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,,, 6 9 0 0 0 0 1
Friedman M, friedman F Fr Fri Frie BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 0 0 0 0 0 0 10 6 ,. 2 9 0 0 0 0 1
JAK1 selectivity jak1 J JA JAK JAK1 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 (-). 4 8 0 0 0 0 1
2018; 2: 2018; 2 20 201 2018 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 6 ;:. 3 1 0 0 0 0 1
7. Voss 7. 7 7. 7. 7. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,,,, 7 9 0 0 0 0 1
et al. et e et et et BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 . 1 9 0 0 0 0 1
in rat in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 6 no 0 8 0 0 0 0 1
subjects. Arthritis subjects. s su sub subj BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 .;:. 4 6 0 0 0 0 1
8. Guttman-Yassky 8. 8 8. 8. 8. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .-,,,, 6 9 0 0 0 0 1
AL, Blauvelt al, A AL AL, AL, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,,.- 4 9 0 0 0 0 1
in adolescents in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 6 -- 2 8 0 0 0 0 1
dermatitis (Measure dermatitis d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 (): 3 8 0 0 0 0 1
two replicate two t tw two two BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 -, 2 8 0 0 0 0 1
trials. Lancet trials. t tr tri tria BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 .;:-. 5 5 0 0 0 0 1
9. Rinvoq® 9. 9 9. 9. 9. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .().., 6 9 0 0 0 0 1
Inc., October inc., I In Inc Inc. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 .,[,].: 7 9 0 0 0 0 1
https://www.rxabbvie.com/pdf/rinvoq_pi.pdf. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf. h ht htt http BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 1 10 6 ://..//.. 9 6 0 0 0 0 1
10. Simpson 10. 1 10 10. 10. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,,, 6 9 0 0 0 0 1
N, et n, N N, N, N, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,. 2 9 0 0 0 0 1
moderate to moderate m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 :- 2 9 0 0 0 0 1
data from data d da dat data BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 no 0 8 0 0 0 0 1
clinical trials. clinical c cl cli clin BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 .;:-. 5 7 0 0 0 0 1
11. Silverberg 11. 1 11 11. 11. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,-, 6 9 0 0 0 0 1
X, Sun x, X X, X, X, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,,. 3 9 0 0 0 0 1
dermatitis patient-reported dermatitis d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 -:- 3 8 0 0 0 0 1
ning severity ning n ni nin ning BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 0 0 0 0 0 0 10 6 no 0 9 0 0 0 0 1
Rating Scale rating R Ra Rat Rati BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 1 0 0 0 0 0 10 6 no 0 8 0 0 0 0 1
Scales (ADerm-SS scales S Sc Sca Scal BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 1 1 0 0 0 0 0 10 6 (--).() 7 8 0 0 0 0 1
2022; 12: 2022; 2 20 202 2022 BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 1 0 0 0 10 6 ;:-. 4 3 0 0 0 0 1
12. de 12. 1 12 12. 12. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .-,,, 5 9 0 0 0 0 1
R, Foley r, R R, R, R, BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,,,.-- 6 9 0 0 0 0 1
atopic dermatitis: atopic a at ato atop BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 :.; 3 8 0 0 0 0 1
103: adv5382. 103: 1 10 103 103: BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 :. 2 2 0 0 0 0 1
13. Yeung 13. 1 13 13. 13. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .,,,,, 6 8 0 0 0 0 1
Lansang P, lansang L La Lan Lans BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,.-- 4 8 0 0 0 0 1
moderate-to-severe atopic moderate-to-severe m mo mod mode BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 --: 3 8 0 0 0 0 1
perspective. J perspective. p pe per pers BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 .;:-. 5 7 0 0 0 0 1
14. de 14. 1 14 14. 14. BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 ALLCAP CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 .-,,,, 6 8 0 0 0 0 1
Silverberg JI, silverberg S Si Sil Silv BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 INITCAP NODIGIT 0 0 0 0 0 0 0 0 10 6 ,,. 3 9 0 0 0 0 1
in adults in i in in in BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 1 1 0 0 0 0 0 10 6 -- 2 8 0 0 0 0 1
dermatitis using dermatitis d de der derm BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 0 0 0 0 0 0 10 6 --.: 4 9 0 0 0 0 1
3rd Annual 3rd 3 3r 3rd 3rd BLOCKIN PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS CONTAINSDIGITS 0 0 0 0 0 0 0 0 10 6 ;-,; 4 8 0 0 0 0 1
virtual meeting. virtual v vi vir virt BLOCKEND PAGEIN SAMEFONT SAMEFONTSIZE 0 0 NOCAPS NODIGIT 0 0 1 0 0 0 0 0 10 6 . 1 2 0 0 0 0 1

